Stockholders’ Equity (Details) - USD ($)																1 Months Ended						12 Months Ended
		Dec. 14, 2023	Nov. 20, 2023	Nov. 08, 2023	Aug. 11, 2023	May 19, 2023	Dec. 30, 2022	Sep. 13, 2022	Aug. 05, 2022	Aug. 01, 2022	Jul. 11, 2022	Feb. 03, 2022	Oct. 22, 2021	Jan. 01, 2021	Dec. 15, 2020	Aug. 31, 2023	Aug. 30, 2023	Aug. 24, 2023	Aug. 16, 2023	Dec. 28, 2022	Aug. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Jul. 08, 2022	Dec. 31, 2021	Feb. 16, 2021
Stockholders’ Equity (Details) [Line Items]
Common stock authorized	[1]																					750,000,000		750,000,000
Common stock par value (in Dollars per share)	[1]																					$ 0.0001		$ 0.0001
Common stock issued										66,667												13,819,889	[1]	12,563,426	[1]
Common stock outstanding	[1]																					13,819,889		12,563,426
Value of grant date (in Dollars)										$ 84,000
Agreement fee (in Dollars)										$ 3,000
Common stock shares																								3,000,000		66,667
Restricted shares									100,000		66,667				83,333
Common stock conversion shares			500,000	289,855		72,464										144,928	2,838	173,914	72,464
Convertible debt (in Dollars)			$ 172,500	$ 100,000		$ 25,000										$ 50,000		$ 60,000	$ 25,000
Shares vested														1,000,000
Remaining vested shares																						50,000
Vested years																						2 years
Shares underlying warrants, granted																						50,000
Expense (in Dollars)																						$ 0		$ 361,064
Preferred stock, authorized																						25,000,000		25,000,000
Preferred stock, par value (in Dollars per share)																						$ 0.0001		$ 0.0001
Description of compensation service																						(i) a cash endorsement fee of Three Hundred Thousand U.S. Dollars ($300,000 USD), payable as follows: (i) One Hundred Twenty-Five Thousand Dollars ($125,000) upon execution of the Endorsement Agreement, (ii) One Hundred Twenty-Five Thousand Dollars ($125,000) quarterly during the Term, beginning on the 90th day following the Effective Date, and (iii) Fifty Thousand Dollars ($50,000) on or prior to the first anniversary of the Effective Date and (ii) warrants exercisable for an aggregate of Five hundred thousand (500,000) shares of the Common Stock at an exercise price of $1.035 per share. The Warrants shall have a three-year term commencing from the Effective Date.
Exercise price (in Dollars per share)								$ 1.2																				$ 0.24
Expiration date																					Aug. 30, 2027
Note amendment transaction description																						the Company entered into the December 2022 Note Amendment Transaction, as fully described in note 11 above. In terms of the Note Amendment Transaction the following occurred:   ● The warrants issued to Cavalry and Mercer exercisable for 165,798 shares of Common Stock (82,899 for each of Cavalry and Mercer), were exchanged for two promissory notes of $482,000 each, as disclosed in note 11 above;   ● The warrants issued to Cavalry and Mercer on August 30, 2022, were subject to repricing and a full rachet increase in the number of warrants issued, resulting in an increase in the number of warrants by 2,408,696 (1,204,348 to each Cavalry and Mercer) and a reset of the exercise price to $0.345 per share. The additional warrants were valued at $841,003 using a Black-Scholes valuation model and was expensed in the statement of operations as a component of the loss on convertible debt.   ● An additional 457,895 warrants previously issued to Mercer, Iroquois Master Fund and Bellridge Capital LP were subject to repricing of the exercise price from a range of $1.50 to $4.50 per share to $0.345 per share. The change in the fair value of these warrants of $20,079, using a Black-Scholes valuation model was recorded as a component of the loss on convertible debt.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number		292,463			33,334																	33,334
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)		$ 0.345			$ 1.5		$ 1.2													$ 0.0115		$ 0.345
Proceeds from Warrant Exercises (in Dollars)		$ 225,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period																						1,000,000
Limitation exceeds percentage																						9.99%
Purchase an aggregate shares																						133,334
Preferred stock, per share amounts of preferred dividends in arrears (in Dollars per share)																						$ 0.45
Purchase shares of common stock																						166,667
Additional purchase shares of common stock																						166,667
Aggregate purchase of common stock																						1,333,334
Warrants outstanding an intrinsic value (in Dollars)																						$ 0		$ 0
Incentive stock options											500,000
Amount of immediate expense (in Dollars)																								31,970
Options exercisable shares								6,667														716,666
Intrinsic value outstanding options (in Dollars)																						$ 0		0
Option expense (in Dollars)																						$ 377,856		$ 1,233,682
Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Warrants beneficially percentage																						4.99%
Shares of common stock																						26,667
Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Purchased shares							1,000,000
Fair value of warrants (in Dollars)							$ 348,938
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)												$ 4.5								$ 0.345			[2]		[2]
Purchase an aggregate shares																						199,999
Incentive stock options	[2]																					10,442,093		5,186,376			1,243,477
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock par value (in Dollars per share)																						$ 0.0001
Common stock issued										2,000,000
Value of grant date (in Dollars)																										$ 84,000
Common stock shares																										2,000,000
Warrant exercisable																					100,000
Exercise price (in Dollars per share)							$ 0.345														$ 4.5
Options exercisable shares								26,668														23,891
Common Stock [Member] | Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Shares of common stock																						100,000
Chief Executive Officer [Member]
Stockholders’ Equity (Details) [Line Items]
Stock option exercise price (in Dollars per share)											$ 4.5
Amount of immediate expense (in Dollars)																								$ 823,854
Debt Conversion Notices [Member]
Stockholders’ Equity (Details) [Line Items]
Aggregate shares of common stock																						5,696,586
Convertible debt amount (in Dollars)																						$ 0.345
2021 Stock Incentive Plan [Member] | Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Shares of common stock													1,766,667
Restricted Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Restricted shares															2,500,000
Shares vested														33,333
Remaining vested shares																						1,500,000
Shares underlying warrants, granted																						1,500,000
2018 Stock Incentive Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Terminates period																						10 years
2021 Stock Incentive Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Terminates period													10 years
Richard Rosenblum [Member]
Stockholders’ Equity (Details) [Line Items]
Restricted shares											2,000,000
Samad Harake [Member]
Stockholders’ Equity (Details) [Line Items]
Value of grant date (in Dollars)									$ 165,000		$ 110,000
Common stock shares									3,000,000

[1] After giving effect to a 1 for 30 reverse stock split on August 30, 2023.

[2] After giving effect to a 1 for 30 reverse stock split on August 30, 2023.